BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28714030)

  • 1. KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.
    Feng T; Wang Y; Lang Y; Zhang Y
    Mol Med Rep; 2017 Sep; 16(3):3573-3580. PubMed ID: 28714030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone demethylase KDM5A enhances cell proliferation, induces EMT in lung adenocarcinoma cells, and have a strong causal association with paclitaxel resistance.
    Xu L; Wu H; Hu X
    Acta Biochim Pol; 2021 Jul; 68(4):593-602. PubMed ID: 34270886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells.
    Li L; Xu QH; Dong YH; Li GX; Yang L; Wang LW; Li HY
    Eur Rev Med Pharmacol Sci; 2016 May; 20(10):2004-10. PubMed ID: 27249598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
    Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
    Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SP1-12LOX axis promotes chemoresistance and metastasis of ovarian cancer.
    Zhang Q; Yan G; Lei J; Chen Y; Wang T; Gong J; Zhou Y; Zhao H; Chen H; Zhou Y; Wu L; Zhang J; Zhang X; Wang J; Li Y
    Mol Med; 2020 May; 26(1):39. PubMed ID: 32375633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
    Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
    Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human chorionic gonadotropin β regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer.
    Liu N; Peng SM; Zhan GX; Yu J; Wu WM; Gao H; Li XF; Guo XQ
    Oncol Rep; 2017 Sep; 38(3):1464-1472. PubMed ID: 28713970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
    Xue YN; Yu BB; Liu YN; Guo R; Li JL; Zhang LC; Su J; Sun LK; Li Y
    Prostate; 2019 May; 79(6):647-656. PubMed ID: 30714183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.
    Wang B; Li S; Meng X; Shang H; Guan Y
    Tumour Biol; 2015 Aug; 36(8):6433-43. PubMed ID: 25801244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
    Wang L; Jia E
    Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
    Wang J; Ye C; Liu J; Hu Y
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
    Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
    Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Controlled release of paclitaxel from microparticles containing PLLA and its anti-tumor activity on human ovarian carcinoma cell line].
    Yang Q; Kang YQ; Wang HJ; Yin GF; Fang K; Yang K
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):212-6. PubMed ID: 19462892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcuma zedoaria (Berg.) Rosc. essential oil and paclitaxel synergistically enhance the apoptosis of SKOV3 cells.
    Zhou Y; Shen J; Xia L; Wang Y
    Mol Med Rep; 2015 Jul; 12(1):1253-7. PubMed ID: 25777341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
    Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
    Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis.
    Sang XB; Sun KX; Wang LL; Chen S; Wu DD; Zong ZH; Zhao Y
    Oncol Rep; 2016 Dec; 36(6):3267-3274. PubMed ID: 27748937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.